Sarepta Signs an Exclusive Global (Except EU) License Agreement with Lysogene for LYS-SAF302 to Treat MPS IIIA
Shots:
- Lysogene to get $26M (€22M) upfront cash with equity investment of $2.5M (€2.2M) at a 30% premium- receive development- regulatory- and commercial milestone payments ~$125 M (€108M) with royalties on sales of product
- Sarepta will get hold of exclusive commercial rights to LYS-SAF302 in the US and and has an option to license CNS Gene therapy candidates for $19M(€16M) & Lysogene will have marketing rights in EU
- LYS-SAF302 is an AAV-mediated gene therapy candidate to replace SGSH gene with a healthy gene. In Q4’18 Lysogene will onset the completion of trial while Sarepta will be undertake global manufacturing rights of LYS-SAF302 and supply Lysogene for its territory
Ref: Sarepta Therapeutics | Image: The Business Journals
Click here to read the full press release
This content piece was prepared by our former Senior Editor. She had expertise in life science research and was an avid reader. For any query reach out to us at connect@pharmashots.com